Skip to Content
  • An Anticoagulant Antidote

    Here’s a drug-discovery problem that you don’t often have to think about. The anticoagulant field is a huge one, with Plavix, warfarin, and plenty o… Read More
  • Regeneron Expands

    I feel as if there should be some good news around here on the hiring front, so when any becomes available I want to try to mention it. So here’s some: Re… Read More
  • Affymax In Trouble

    Affymax has had a long history, and it’s rarely been dull. The company was founded in 1988, back in the very earliest flush of the Combichem era, and in i… Read More
  • Merck Finally Settles Over Vytorin

    You may remember that Merck and Schering-Plough took a lot of fire for the way that they released the clinical data for one of the key Vytorin trials (ENHANCE). Read More
  • Mipomersen In Trouble

    I wrote here in 2009 about Kynamro (mipomersen), an antisense oligonucleotide from Isis targeted LDL cholesterol levels. At the time, Isis and Genzyme were star… Read More
  • Eli Lilly’s Drumbeat of Bad News

    Eli Lilly has been getting shelled with bad news recently. There was the not-that-encouraging-at-all failure of its Alzheimer’s antibody solanezumab to me… Read More
Page 5 of 17« First...34567...10...Last »